Vancouver, British Columbia, Canada, November 4, 2025 – TheNewswire - P anGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA, FSE:LL3) is pleased to announce that it has entered into a non-binding letter of intent (the “LOI”) with Ayla BioScience, Inc., a company formed under the laws of Delaware, USA (“Ayla BioScience”) to enter into an exclusive distribution agreement and a share purchase agreement.... Read More

Vancouver, British Columbia, Canada, October 20, 2025 – TheNewswire - PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA, FSE:LL30) is pleased to announce that it has launched a DNA testing program as part of its Nara.Care AI platform for personalized wellness. Working with a leading developer of DNA testing technologies, the Company will market its Agenta branded DNA testing kits to health-conscious... Read More

Vancouver, British Columbia, Canada, October 7, 2025 – TheNewswire - PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA, FSE:LL30) is pleased to announce that it has expanded its engagement with Fairfax Partners Inc. (“Fairfax”) of Vancouver, BC for the provision of investor relations, communications infrastructure and marketing services. The original services agreement with Fairfax was announced by the... Read More

Vancouver, British Columbia, Canada, September 23, 2025 – TheNewswire - PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA, FSE:LL30) is pleased to announce that its wholly-owned subsidiary, Mindleap Health Inc. (“Mindleap Health"), plans to establish its Health AI Centre operations in Hong Kong. “Mindleap Health is developing a real-world evidence (“RWE”) platform for the Complementary & Alternative... Read More

Vancouver, British Columbia, Canada – TheNewswire - September 9, 2025 – PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA, FSE:LL30) is pleased to announce that its wholly-owned subsidiary, Mindleap Health Inc. (“Mindleap Health"), is developing a real-world evidence (“RWE”) platform for the Complementary & Alternative Medicine (“CAM”) market. “With profound changes taking place in the U.S. Food and... Read More

Vancouver, British Columbia, Canada – TheNewswire - August 26, 2025 – PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA) is pleased to announce that it will attend and be a sponsor of the Vivacity trade conference, providing a strategic opportunity to showcase the Company's recently announced Agenta Health e-Commerce platform. The Vivacity Medical Aesthetics & Healthy Aging Show will take place in... Read More

Vancouver, British Columbia, Canada – TheNewswire - August 19, 2025 – PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) is pleased to announce that it has launched its new eCommerce shopping site, a key component of the NaraCare.AI platform strategy previously announced on July 25, 2025. Agenta Health “The Agenta Health eCommerce site is the springboard for our NaraCare.AI platform”, said Maryam... Read More

Vancouver, British Columbia, Canada, July 25, 2025 – TheNewswire - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) is pleased to provide a corporate update on recent strategic initiatives. NaraCare.AI Platform Strategy “PanGenomic Health is pleased to announce that it is developing a new AI health platform for personalized alternative health products”, said Maryam Marissen, President & CEO of... Read More

Vancouver, British Columbia, Canada, July 11, 2025 – TheNewswire - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) is pleased to announce the appointment of Manpreet Dhillon as a director of the Company. Ms. Dhillon has over 20 years of international consulting experience specializing in implementing programs on economic empowerment, gender equality, and stakeholder engagement for international... Read More

Vancouver, British Columbia, Canada – TheNewswire - July 2, 2025 – PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) is pleased to announce that it has filed its audited annual consolidated financial statements for the financial year ended December 31, 2024 (the “2024 Year End Financial Statements”). The 2024 Year End Financial Statements, together with detailed information regarding the Company's... Read More

Vancouver, British Columbia, Canada – TheNewswire - June 26, 2025 – PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA), further to its news release of June 12, 2025 (the “Third MCTO Update”), provides an update with respect to the management cease trade order (the “MCTO”) dated May 1, 2025 issued by the British Columbia Securities Commission (the “BCSC”) in connection with the delay by the Company in... Read More

Vancouver, British Columbia, Canada – TheNewswire - April 3, 2025 – PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) announces the resignation of Tammy Gillis as CFO of the Company. Ms. Gillis will continue to act as a financial consultant to the Company, and in particular, assist with completion of the year end audit process for the last fiscal year. Current director Francisco Kent Carasquero will... Read More

Vancouver, British Columbia, January 10, 2025 – TheNewswire - PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA) is pleased to announce it has completed its private placement offering (the " Offering ") of an aggregate of 7,500,000 units of the Company (the “ Units ”) at a price of $0.10 per Unit for gross proceeds of $750,000, consisting of $50,000 in cash and the settlement of outstanding... Read More

Vancouver, British Columbia, Canada – TheNewswire - January 9, 2025 – PanGenomic Health Inc. (“PanGenomic ” or the “Company ” ) (CSE: NARA), announced that it intends to amend the exercise price of a total of 4,300,464 share purchase warrants (the “ Warrants ”) having a current exercise price of $0.50 per share (on a post-consolidation basis) to $0.17 per share (the “ Warrant Repricing ”). Effectiveness of the proposed... Read More

Vancouver, British Columbia, December 31, 2024 – TheNewswire - PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA) is pleased to announce a private placement offering (the " Offering ") of an aggregate of up to 7,500,000 units of the Company (the “ Units ”) at a price of $0.10 per Unit for gross proceeds, and to settle outstanding indebtedness, of up to an aggregate of $750,000 (the “Offering”). Each... Read More

Vancouver, British Columbia, November 14, 2024 – TheNewswire – PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) announces the completion of the consolidation (the “Consolidation”) of all of its issued and outstanding Class A Common Shares (“Common Shares”) on the basis of five (5) pre-Consolidation Common Shares for every one (1) post-Consolidation Common Share was completed, effective November 14,... Read More

Vancouver, British Columbia, November 7, 2024 - TheNewswire – PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) announces that it intends to consolidate all of its issued and outstanding Class A Common Shares (the “Common Shares”) on the basis of five (5) pre-Consolidation Common Shares for every one (1) post-Consolidation Common Share (the “Consolidation”). There are currently 31,999,068 Common... Read More

Vancouver, British Columbia, Canada – TheNewswire - July 30, 2024 – PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) is pleased to announce that it has filed its audited annual consolidated financial statements for the financial year ended December 31, 2023 (the “2023 Year End Financial Statements”) and interim consolidated financial statements for the three months ended March 31, 2024 (the "Q1... Read More

Vancouver, British Columbia – TheNewswire - May 27, 2024 – PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA) is pleased to announce that the Company has completed its previously announced settlement of outstanding indebtedness in the amount of $1,075,116 through a private placement offering (the " Offering ") of an aggregate of 21,502,320 units (the “ Units ”) of the Company at a price of $0.05 per... Read More

VANCOUVER, BC , April 12, 2024 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) announces that it has made an application to the British Columbia Securities Commission to approve a management cease trade order ("MCTO") under National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203"), which, if granted, will prohibit the Chief Executive Officer and Chief... Read More

VANCOUVER, BC , March 21, 2024 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) announces the completion of the consolidation (the "Consolidation") of all of its issued and outstanding Class A Common Shares ("Common Shares") on the basis of ten (10) pre-Consolidation Common Shares for every one (1) post-Consolidation Common Share was completed, effective March 21, 2024 . Immediately upon... Read More

Toronto, Ontario--(Newsfile Corp. - Le 19 mars/March 2024) - PanGenomic Health Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every ten (10) pre-consolidated common shares. As a result, the outstanding shares of the company will be reduced to approximately 10,496,746 common shares. The name and symbol will not change. Please note that... Read More

VANCOUVER , March 18, 2024 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) announces that it intends to consolidate (the "Consolidation") all of its issued and outstanding Class A Common Shares ("Common Shares") on the basis of ten (10) pre-Consolidation Common Shares for every one (1) post-Consolidation Common Share. There are currently 104,967,459 issued and outstanding. Upon completion of... Read More

VANCOUVER, BC , Feb. 20, 2024 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) (AQSE: NARA) announces its intention to withdraw the Company's Class A Common Shares ("Shares") from the Aquis Stock Exchange Growth Market ("AQSE"). Pursuant to the AQSE Access Rulebook, the Company is required to give 20 business days' notice of its intention to withdraw from trading on AQSE. Therefore, trading... Read More

VANCOUVER, BC , Feb. 16, 2024 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) (AQSE: NARA) announces changes to its board of directors. The Company announces the resignation of Vincent Lum as a director of the Company. Mr. Lum, the previous CEO and a co-founder of PanGenomic Health, will continue to serve as the CEO, President, Executive Chair and a director of the Company's subsidiary, MUJN... Read More

VANCOUVER, BC , Jan. 9, 2024 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) (AQSE: NARA), is pleased to announce that it has entered into a non-binding letter of intent with Crescita Capital LLC ("Crescita Capital") for a $5 million equity drawdown facility ("Equity Drawdown Facility"). Under the proposed non-revolving Equity Drawdown Facility, PanGenomic Health will have three years to... Read More

VANCOUVER, BC , Dec. 6, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) (AQSE: NARA), is pleased to announce that its subsidiary, MUJN Diagnostics Inc. ("MUJN Diagnostics"), has introduced its point-of-care Vitamin D test for the dental implant industry. "Vitamin D can play a significant role in the success of a dental implant procedure", said Dr. William Liang , Diplomate of the... Read More

VANCOUVER, BC , Nov. 17, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) (AQSE: NARA), is pleased to announce that its subsidiary, MUJN Diagnostics Inc . ("MUJN Diagnostics"), has launched its BDNF (brain-derived neurotrophic factor) mental health biomarker health assessment service and completed its first sale of the point-of-care test marketed to health clinics in Canada . "Our... Read More

VANCOUVER, BC , Nov. 1, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic" or the "Company") (CSE: NARA) (AQSE:NARA) is pleased to announce that, further to its news release dated 9 August 2023 , the Company intends to complete the shares-for-debt transaction (the " Debt Settlement Transaction ") with certain creditors of the Company, pursuant to which the Company will settle $281,964.51 of indebtedness through the issuance... Read More

VANCOUVER, BC , Aug. 30, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) (AQSE: NARA), is pleased to announce that it has filed financial statements for the six month period ended June 30, 2023 (the "First Half 2023 Financial Statements"). The First Half 2023 Financial Statements, together with detailed information regarding the Company's financial results as set forth in the Company's... Read More

VANCOUVER, BC , Aug. 9, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic" or the "Company") (CSE: NARA) (AQSE: NARA) is pleased to announce that Traktor Beam Media Strategies Inc. ("TB") has been retained to provide social media engagement and audience procurement services (the "Services"). Under the terms of the agreement, TB will provide the Services at a monthly cost to the Company of $13,500 USD over an expected... Read More

VANCOUVER, BC , July 13, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) (AQSE: NARA), announced today that independent directors, Peter Green and Jonathan Lutz , tendered their resignations effective as of July 12, 2023 . "We wish to thank Peter and Jonathan for all of their valuable guidance as PanGenomic matured from a private health tech startup to one of the first publicly-listed... Read More

VANCOUVER, BC , July 6, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) (AQSE: NARA), is pleased to announce that its subsidiary, MUJN Diagnostics Inc. ("MUJN Diagnostics"), has commenced a Vitamin D health assessment service and has also launched a corporate website at mujn.ai . "We are very excited to introduce the MUJN biomarker assessment platform at Vancouver -based Empower Health... Read More

VANCOUVER, BC , June 6, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) (AQSE: NARA), is pleased to provide an update on its NARA product and announce that it is planning to launch conversational AI for the NARA app and web platform ("Conversational AI"). The Company released a new version of its NARA app this quarter with an updated plant library, plant rating system, expanded video... Read More

VANCOUVER, BC , May 30, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) (AQSE: NARA), is pleased to announce that it has entered into a non-binding letter of intent dated May 26, 2023 ("LOI") with Interactive Health Inc. ("IHI"), whereby PanGenomic Health will license IHI's CyberPatient AI medical education platform ("CyberPatient AI Platform") for the exclusive use in the consumer,... Read More

VANCOUVER, BC , May 2, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) (AQSE: NARA), is pleased to announce that it has filed its audited annual financial statements for the fiscal year ended December 31, 2022 (the "2022 Year End Financial Statements"). The 2022 Year End Financial Statements, together with detailed information regarding the Company's financial results as set forth in... Read More

VANCOUVER, BC , May 2, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) (AQSE: NARA), is pleased to announce the results of its Annual General Meeting held on April 26, 2023 (the "Meeting"). All Company matters submitted to shareholders for approval as set out in the Company's Notice of Meeting and Management Information Circular, dated March 21, 2023 (the "Information Circular"), were... Read More

VANCOUVER, BC , April 21, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) (AQSE: NARA), is pleased to announce that, further to the announcement made on January 26, 2023 , its subsidiary, MUJN Diagnostics Inc. ("MUJN Diagnostics"), has signed a definitive master services agreement ("MSA") with Psy Integrated Health, Inc. ("Psyi"), a management services organization. MUJN Diagnostics'... Read More

VANCOUVER, BC , April 12, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic" or the "Company") (CSE: NARA) (AQSE: NARA), is pleased to announce that it has completed its admission to the Access segment of the Aquis Stock Exchange ("AQSE") and trading will commence at 8:00 a.m. GMT on April 12, 2023 under the ticker "NARA" and with its existing ISIN CA 69842E 20 5 0. The Company's shares will also continue to trade on the... Read More

VANCOUVER, BC , April 6, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic" or the "Company") (CSE: NARA) is pleased to announce that Yellow Jersey PR Limited ("Yellow Jersey") has been retained to provide investor relations and digital marketing services (the "Services"). Under the terms of the agreement, Yellow Jersey will provide a combination of public relations, investor relations advisory services, content development,... Read More

VANCOUVER, BC , March 30, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA), is pleased to announce its subsidiary, MUJN Diagnostics Inc. ("MUJN Diagnostics"), has signed a master services agreement with Hemex Health Inc. ("Hemex Health"), a Portland, Oregon -based medical diagnostic device company focused on developing life changing testing solutions for the point-of-care market. Hemex... Read More

VANCOUVER, BC , March 28, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA), is pleased to announce the filing of its business acquisition report (the "BAR") relating to its acquisition of all outstanding shares of Mindleap Health Inc. ("Mindleap") previously announced on December 12, 2022 . In accordance with Part 8 of National Instrument 51-102 - Continuous Disclosure Obligations , the... Read More

VANCOUVER, BC , March 22, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA), is pleased to announce its subsidiary, MUJN Diagnostics Inc. ("MUJN Diagnostics"), is collaborating with Circle Innovation, a non-profit facilitator of technology solutions and innovation based in Vancouver . The collaboration project will include up to $80,000 in financial support from Circle Innovation for the... Read More

VANCOUVER, BC , March 8, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA), is pleased to announce that its new Women's DNA Report is now available and that it has expanded into new geographic markets for its NARA wellness health app. With the launch of the e-commerce nara.care website in February 2023 , the Company expanded NARA's focus beyond the mental health category. The Company has... Read More

VANCOUVER, BC , March 2, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA), is pleased to provide a corporate update on its strategic initiatives. Acquisition of Mindleap Health Inc. In December 2022 , the Company completed the acquisition of Mindleap Health Inc. ("Mindleap") and its Mindleap app (the "Mindleap App"). The Mindleap App is a virtual health and inner wellness platform that... Read More

VANCOUVER, BC , Feb. 9, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA), is pleased to announce that, further to the announcement made on January 9, 2023 , the Company has launched its new visual identity, website and e-commerce store for its NARA brand, available at nara.care. The NARA e-commerce platform offers curated information about natural supplements and lifestyle products, all... Read More

VANCOUVER, BC , Feb. 2, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA), is pleased to announce that, further to the announcement made on January 26, 2023 , its subsidiary, MUJN Diagnostics Inc. (formerly named PlantGx Diagnostics Corp.)("MUJN Diagnostics"), has signed an agreement to lease space at Psy Integrated Health, Inc.'s ("Psyi") Empower Health Wellness Centre clinic facility... Read More

VANCOUVER, BC , Jan. 31, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA), is pleased to announce its intention to apply for admission to trading on the Aquis Stock Exchange Growth Market ("AQSE") in the UK. Novum Securities Ltd. has been appointed as the Company's AQSE Corporate Adviser in the UK, and has submitted its suitability review letter to the AQSE. PanGenomic Health is... Read More

VANCOUVER, BC , Jan. 26, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA), is pleased to announce its subsidiary, MUJN Diagnostics Inc. (formerly named PlantGx Diagnostics Corp.)("MUJN Diagnostics"), has signed a non-binding memorandum of understanding ("MoU") for a diagnostic testing joint venture with Psy Integrated Health Inc. ("Psyi"), a Vancouver -based management services... Read More

VANCOUVER, BC , Jan. 23, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA), is pleased to announce that its Nara Plant Library is available now on the Nara app as a resource to provide science-backed information about natural remedy alternatives to pharmaceutical drugs. Pangenomic Health also announces that its Nara app now also complies with US Federal Trade Commission ("FTC")... Read More

VANCOUVER, BC , Jan. 20, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA), is pleased to announce the soft launch of the "NARA DNA Reports" feature available through its website nara.care . The Company has launched its first report of a series, the NARA MIND Report as its debut product which can be purchased for $189.00 USD . Additionally, the Company announced today that, further to its... Read More

VANCOUVER, BC , Jan. 16, 2023 /CNW/ - P anGenomic Health Inc. ( "PanGenomic Health" or the "Company") (CSE: NARA) (FSE: LL30) is pleased to announce that its newly-acquired subsidiary, Mindleap Health Inc. ("Mindleap") will be extending its current programs and practitioner specialties this quarter to enable an all-in-one app and telehealth platform for holistic mental wellness. According to the National Institute of Mental... Read More

VANCOUVER, BC , Jan. 12, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) is pleased to announce that its subsidiary, PlantGx Diagnostics Corp. ("PlantGx"), has signed a development partnership agreement with LumiQuick Diagnostics, Inc., a Santa Clara-based medical device company ("LumiQuick "). The two companies are jointly developing targeted biomarker diagnostics to help patients... Read More

VANCOUVER, BC , Jan. 9, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) is pleased to announce that it plans to launch its e-commerce platform for personalized natural health solutions this month. Built as an extension to its Nara consumer app and website launched in 2022, the e-commerce platform on nara.care will market its proprietary natural herbal remedy information library and... Read More

VANCOUVER, BC , Jan. 3, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic" or the "Company") (CSE: NARA) is pleased to announce that Bello Capital Partners ("Bello") has been retained to provide capital markets advisory and digital marketing services (the "Services"). Under the terms of the agreement, Bello will provide a combination of capital market and investor relations advisory services, content development, web... Read More

VANCOUVER, BC , Dec. 23, 2022 /CNW/ - PanGenomic Health Inc. ("PanGenomic" or the "Company") (CSE: NARA) is pleased to announce that it has initiated a non-brokered private placement financing of up to 3,333,333 units (each a "Unit") at a price of $0.15 per Unit, for total gross proceeds of up to $500,000 (the "Offering"). The Company further announces that it has closed a first tranche under the Offering for gross proceeds... Read More

VANCOUVER, BC , Dec. 22, 2022 /CNW/ - PanGenomic Health Inc. ("PanGenomic" or the "Company") (CSE: NARA) today issued a letter to shareholders from its executive team. Dear Shareholders, As we close out our first year as a publicly-traded company, your team at PanGenomic Health is busy laying the groundwork for success in the burgeoning health technology industry. At the core of our evidence-based health platform is an... Read More

VANCOUVER, BC , Dec. 12, 2022 /CNW/ - PanGenomic Health Inc. ("PanGenomic" or the "Company") (CSE: NARA), is pleased to announce, further to its news releases dated September 1, 2022 and November 21, 2022 , the completion of its previously announced acquisition (the "Transaction") of Mindleap Health Inc. ("Mindleap") from Mydecine Innovations Group Inc. ("Mydecine"), a company listed on the NEO Exchange (the "NEO"). "We are... Read More